Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2045893217702401 http://scihub22266oqcxt.onion/10.1177/2045893217702401 C5467933!5467933!28597752     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pulm+Circ 2017 ; 7 (2): 439-47 Nephropedia Template TP {{tp|p=28597752|t=2017. Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) |pdf=|usr=}}{{28597752}} gab.com Text Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) JO: Pulm Circ http://www.kidney.de/pget.php?&tw=1&pmid=28597752 #FOAvip Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated eight PAH participants transitioned from epoprostenol to PAH oral drugs. The criteria for epoprostenol withdrawal were: (1) persistent improvement of clinic and hemodynamic status; (2) stable dose of epoprostenol for the last three months; and (3) the participant?s preference for oral therapy after evaluation of risk-benefit. We evaluated the clinical, functional, and hemodynamic status at baseline, at withdrawal, and after the transition to oral PAH therapy. The transition was completed in all eight participants. Four participants had a complete successful transition (CT) with a stable clinical and hemodynamic course and four participants had a partial successful transition (PT) remaining stable clinically, with a mild hemodynamic worsening, but without need to re-initiate epoprostenol therapy. The four CT participants were treated with epoprostenol for a shorter period of time (CT group: 35?±?30 versus PT group: 79?±?49 months, P?=?0.08). Mean epoprostenol dosage was lower in the CT group (CT group: 15?±?1.5?ng/kg/min versus PT group: 24?±?11?ng/kg/min, P?=?0.09). Safe withdrawal of epoprostenol treatment and transition to oral PAH therapy was possible in a small and highly selected group of participants. The majority of these participants had a porto-pulmonary PAH or PAH associated to HIV infection. Twit Text FOAVip Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) ????Pulm Circ http://www.kidney.de/pget.php?&tw=1&pmid=28597752 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28597752 #FOAvip English Wikipedia <ref>{{Cite pmid|28597752}}</ref> Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) #MMPMID28597752 Calcaianu G; Calcaianu M; Canuet M; Enache I; Kessler R Pulm Circ 2017[Jun]; 7 (2): 439-47 PMID28597752show ga Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated eight PAH participants transitioned from epoprostenol to PAH oral drugs. The criteria for epoprostenol withdrawal were: (1) persistent improvement of clinic and hemodynamic status; (2) stable dose of epoprostenol for the last three months; and (3) the participant?s preference for oral therapy after evaluation of risk-benefit. We evaluated the clinical, functional, and hemodynamic status at baseline, at withdrawal, and after the transition to oral PAH therapy. The transition was completed in all eight participants. Four participants had a complete successful transition (CT) with a stable clinical and hemodynamic course and four participants had a partial successful transition (PT) remaining stable clinically, with a mild hemodynamic worsening, but without need to re-initiate epoprostenol therapy. The four CT participants were treated with epoprostenol for a shorter period of time (CT group: 35?±?30 versus PT group: 79?±?49 months, P?=?0.08). Mean epoprostenol dosage was lower in the CT group (CT group: 15?±?1.5?ng/kg/min versus PT group: 24?±?11?ng/kg/min, P?=?0.09). Safe withdrawal of epoprostenol treatment and transition to oral PAH therapy was possible in a small and highly selected group of participants. The majority of these participants had a porto-pulmonary PAH or PAH associated to HIV infection. äWithdrawal of long-term epoprostenol therapy in pulmonary arterial hyp(epmc).pdf DeepDyve Pubget Overpricing